<DOC>
	<DOCNO>NCT02927301</DOCNO>
	<brief_summary>This study design evaluate safety efficacy neoadjuvant adjuvant atezolizumab participant Stage IB , II , IIIA NSCLC eligible surgical resection curative intent . Neoadjuvant therapy consist two 21-day cycle atezolizumab . Following surgery , adjuvant therapy consist 12 month atezolizumab participant demonstrate clinical benefit neoadjuvant therapy .</brief_summary>
	<brief_title>A Study Atezolizumab Neoadjuvant Adjuvant Therapy Stage IB , II , IIIA Resectable Untreated Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologically document Stage IB , II , IIIA NSCLC eligible surgical resection curative intent Adequate pulmonary cardiac function Available biopsy primary tumor adequate sample Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic endorgan function Agreement remain abstinent use appropriate contraception , among woman childbearing potential NSCLC clinically tumor size T3 virtue multiple tumor nodule within lobe Any prior therapy lung cancer Prior treatment antiPD1 PDL1 therapy Major surgery within 28 day prior Day 1 Cycle 1 Malignancies NSCLC within 3 year prior Day 1 Cycle 1 except curatively treated malignancy negligible risk metastasis death History risk autoimmune disease Hepatitis B C human immunodeficiency virus ( HIV ) infection Administration live attenuate vaccine within 4 week Day 1 Cycle 1 Severe infection within 4 week prior Day 1 Cycle 1 Treatment investigational agent within 4 week five halflives prior Day 1 Cycle 1 History severe hypersensitivity chimeric humanize antibody fusion protein Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>